Zacks: Analysts Anticipate Tilray Inc (NASDAQ:TLRY) to Post -$0.23 EPS

Wall Street brokerages expect Tilray Inc (NASDAQ:TLRY) to announce earnings per share (EPS) of ($0.23) for the current quarter, Zacks reports. Seven analysts have issued estimates for Tilray’s earnings, with the lowest EPS estimate coming in at ($0.35) and the highest estimate coming in at ($0.12). Tilray reported earnings of ($0.17) per share during the same quarter last year, which indicates a negative year over year growth rate of 35.3%. The firm is scheduled to report its next earnings report on Tuesday, August 27th.

According to Zacks, analysts expect that Tilray will report full year earnings of ($0.92) per share for the current year, with EPS estimates ranging from ($1.38) to ($0.42). For the next financial year, analysts forecast that the company will report earnings of ($0.37) per share, with EPS estimates ranging from ($1.05) to $0.24. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Tilray.

Tilray (NASDAQ:TLRY) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.02). Tilray had a negative return on equity of 43.71% and a negative net margin of 159.09%. The company had revenue of $23.00 million for the quarter, compared to analysts’ expectations of $20.50 million. The company’s revenue was up 194.9% on a year-over-year basis.



TLRY has been the topic of several analyst reports. Stifel Nicolaus reduced their price target on MacroGenics from $36.00 to $29.00 and set a “buy” rating on the stock in a report on Wednesday, June 5th. Vertical Research downgraded Potlatchdeltic from a “buy” rating to a “hold” rating and set a $39.00 target price on the stock. in a research report on Friday, April 12th. Jefferies Financial Group increased their target price on Monster Beverage from $65.00 to $70.00 and gave the stock a “buy” rating in a research report on Friday, May 3rd. Oppenheimer assumed coverage on Tilray in a research report on Tuesday, June 4th. They set a “market perform” rating on the stock. Finally, Alliance Global Partners set a C$75.00 target price on Canopy Growth and gave the stock a “buy” rating in a research report on Monday, May 13th. Four research analysts have rated the stock with a sell rating, nine have issued a hold rating and four have assigned a buy rating to the company’s stock. Tilray has a consensus rating of “Hold” and a consensus target price of $76.97.

In other news, Director Christine St.Clare sold 4,000 shares of the firm’s stock in a transaction dated Thursday, June 20th. The stock was sold at an average price of $50.01, for a total value of $200,040.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 3.40% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. Lee Financial Co acquired a new stake in Tilray during the first quarter valued at $25,000. Quantamental Technologies LLC bought a new stake in Tilray in the first quarter valued at $26,000. PNC Financial Services Group Inc. increased its stake in Tilray by 105.8% in the first quarter. PNC Financial Services Group Inc. now owns 463 shares of the company’s stock valued at $30,000 after purchasing an additional 238 shares in the last quarter. Synovus Financial Corp increased its stake in Tilray by 2,500.0% in the first quarter. Synovus Financial Corp now owns 1,040 shares of the company’s stock valued at $69,000 after purchasing an additional 1,000 shares in the last quarter. Finally, Bronfman E.L. Rothschild L.P. increased its stake in Tilray by 7,266.7% in the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 1,105 shares of the company’s stock valued at $78,000 after purchasing an additional 1,090 shares in the last quarter. Institutional investors own 2.10% of the company’s stock.

Shares of NASDAQ TLRY traded up $0.18 during trading on Friday, hitting $43.59. 1,185,205 shares of the company were exchanged, compared to its average volume of 1,240,875. Tilray has a 12-month low of $21.50 and a 12-month high of $300.00. The company has a debt-to-equity ratio of 1.13, a current ratio of 2.35 and a quick ratio of 2.06. The company’s fifty day moving average is $43.48. The stock has a market cap of $4.24 billion and a price-to-earnings ratio of -53.16.

Tilray Company Profile

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.

Recommended Story: What does a neutral rating on stocks mean?

Get a free copy of the Zacks research report on Tilray (TLRY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tilray (NASDAQ:TLRY)

Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.